Scarica l'app Stockscreener
12.78
0.12%
-0.015
Dopo l'orario di chiusura:
12.78
0.005
+0.04%
Precedente Chiudi:
$12.79
Aprire:
$12.79
Volume 24 ore:
436.46K
Relative Volume:
1.22
Capitalizzazione di mercato:
$527.85M
Reddito:
$313.73M
Utile/perdita netta:
$-31.39M
Rapporto P/E:
-16.82
EPS:
-0.7597
Flusso di cassa netto:
$-3.53M
1 W Prestazione:
-1.58%
1M Prestazione:
+5.58%
6M Prestazione:
+26.86%
1 anno Prestazione:
+37.07%
Intervallo 1D:
$12.71
$13.01
Intervallo di 1 settimana:
$12.55
$13.26
Portata 52W:
$8.36
$13.99
Angiodynamic Inc Stock (ANGO) Company Profile
Nome
Angiodynamic Inc
Settore
Industria
Telefono
(518) 798-1215
Indirizzo
14 PLAZA DRIVE, LATHAM
Compare ANGO vs ISRG, BDX, MDLN, ALC, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANGO
Angiodynamic Inc
|
12.78 | 528.47M | 313.73M | -31.39M | -3.53M | -0.7597 |
ISRG
Intuitive Surgical Inc
|
407.12 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
153.83 | 41.87B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
40.58 | 34.70B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
69.00 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
198.50 | 29.57B | 5.54B | 1.52B | 1.74B | 10.37 |
Angiodynamic Inc Stock (ANGO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-16 | Iniziato | Lake Street | Buy |
| 2024-04-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-09-25 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-10-15 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-08-20 | Iniziato | Oppenheimer | Perform |
| 2020-11-25 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2020-04-08 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-01 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2018-04-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-01-05 | Downgrade | Craig Hallum | Buy → Hold |
| 2017-04-07 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-03-30 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| 2017-02-08 | Iniziato | Barclays | Equal Weight |
| 2016-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-04-08 | Ripresa | Piper Jaffray | Neutral |
| 2016-01-08 | Reiterato | Canaccord Genuity | Buy |
| 2015-11-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-07-24 | Iniziato | KeyBanc Capital Mkts | Overweight |
| 2014-06-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2012-10-09 | Reiterato | Canaccord Genuity | Hold |
| 2012-06-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2011-07-15 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2011-07-15 | Aggiornamento | Stifel Nicolaus | Hold → Buy |
| 2011-06-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2010-09-08 | Reiterato | Wedbush | Neutral |
Mostra tutto
Angiodynamic Inc Borsa (ANGO) Ultime notizie
AngioDynamics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANGOAngiodynamic Inc Latest SEC Filings - Finviz
Price to sales forward of AngioDynamics, Inc. – NASDAQ:ANGO - TradingView
Price to sales forward of AngioDynamics, Inc. – LS:A0B9A5 - TradingView
Press Release: AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026 - Moomoo
AngioDynamics sets July 14 call for fiscal 2026 results - Stock Titan
AngioDynamics, Inc.(NasdaqGS: ANGO) added to Russell 2000 Value-Defensive Index - marketscreener.com
AngioDynamics, Inc. Actuals & Estimates (NASDAQ:ANGO) - TradingView
ANGO Forecast — Price Target — Prediction for 2027 - TradingView
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now - TradingView
AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis - TradingKey
AngioDynamics Inc (ANGO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AngioDynamics wins FDA okay to test NanoKnife in BPH patients - Stock Titan
AngioDynamics Inc (ANGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AngioDynamics Inc (ANGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AngioDynamics Inc (ANGO) Institutional Confidence - TradingKey
AngioDynamics Inc (ANGO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow - Seeking Alpha
ANGO News | ANGIODYNAMICS INC (NASDAQ:ANGO) - ChartMill
Port Catheter Thrombosis Lawsuit Claims Defective AngioDynamics Xcela Device Caused Injury - AboutLawsuits.com
ANGO Technical Analysis & Stock Price Forecast - Intellectia AI
ANGO Stock Price, Quote & Chart | ANGIODYNAMICS INC (NASDAQ:ANGO) - ChartMill
Webcast set for AngioDynamics talk at Goldman Sachs health event - Stock Titan
Reasons to Add AngioDynamics Stock to Your Portfolio for Now - Yahoo Finance
Point72 (ANGO) reports 3.18M shares, 7.7% stake via Point72 Associates - Stock Titan
Prostate cancer trial sees 0 new failures with NanoKnife at 2 years - Stock Titan
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet - Yahoo Finance
AngioDynamics alleges patent infringement by E2 over clot removal technology - MassDevice
[8-K] ANGIODYNAMICS INC Reports Material Event - Stock Titan
Fair Value Assessment | AngioDynamics Inc. posts 117.8% EPS surprise beating loss estimatesEarnings Risk - Cổng thông tin điện tử tỉnh Tây Ninh
AngioDynamics files patent lawsuit against Endovascular Engineering - Investing.com
ANGO (AngioDynamics Inc.) notches massive Q1 2026 EPS beat, but shares fall 1.24 percent on slight year over year revenue decline.Social Trade Signals - Xã Thanh Hà
AngioDynamics (ANGO) Upgraded to Buy: Here's Why - Yahoo Finance
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down - TradingView
AngioDynamics Growing, But With More Noise Than The Street Likes (NASDAQ:ANGO) - Seeking Alpha
AngioDynamics Inc. Q3 2026 Financial Results: Revenue, Net Loss, and Key Financial Statements Overview - Minichart
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2026 Earnings Call Transcript - Insider Monkey
AngioDynamics (NASDAQ: ANGO) Q3 2026 revenue up 9% while net loss grows - Stock Titan
AngioDynamics, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
AngioDynamics, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:ANGO) 2026-04-02 - Seeking Alpha
AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance - ChartMill
ANGIODYNAMICS ($ANGO) Releases Q3 2026 Earnings | ANGO Stock News - Quiver Quantitative
AngioDynamics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
AngioDynamics investors can watch Needham conference webcast April 14 - Stock Titan
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 18.0% - Defense World
AngioDynamics, Inc. (NASDAQ:ANGO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
AngioDynamics, Inc. (ANGO) Investor Outlook: Unpacking A 71.55% Potential Upside - DirectorsTalk Interviews
Vanguard disaggregates holdings; reports 0 shares in AngioDynamics (ANGO) - Stock Titan
AngioDynamics, Inc. (ANGO) Stock Analysis: A Potential 81.88% Upside For Investors - DirectorsTalk Interviews
AngioDynamics schedules April 2 earnings call before market open - Stock Titan
Bard And AngioDynamics Resolve 11-Year Patent Dispute - Law360
Angiodynamic Inc Azioni (ANGO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Angiodynamic Inc Azioni (ANGO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Trowbridge Stephen A | EVP and CFO |
Oct 13 '25 |
Buy |
11.16 |
890 |
9,932 |
256,629 |
| Clemmer James C | President and CEO |
Oct 09 '25 |
Buy |
11.15 |
10,000 |
111,500 |
882,529 |
0.22%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):